MarketPulse

Vistagen Therapeutics

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Vistagen Investors Pursue Securities Fraud Claims Over Misleading Drug Trial Statements

Schall Law Firm seeks Vistagen investors in class action over alleged false statements regarding fasedienol drug candidate's Phase 3 trial prospects.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Investors Face March 16 Deadline in Securities Lawsuit Over Trial Disclosures

Rosen Law Firm urges Vistagen investors to join securities class action by March 16, 2026, over alleged misstatements regarding fasedienol and clinical trials.
VTGNsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Therapeutics Faces Securities Class Action Over Drug Trial Disclosure Allegations

Rosen Law Firm announces March 16, 2026 deadline for investors to join securities class action against Vistagen Therapeutics ($VTGN) over alleged misleading statements regarding fasedienol drug trial.
VTGNsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Investors Face March Deadline in Securities Litigation Over Trial Disclosures

Vistagen faces securities lawsuit over misleading trial disclosures. Investors must nominate lead plaintiff by March 16, 2026 deadline.
VTGNsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Filed Against Vistagen Over Alleged Misstatements on Drug Trial

Class action lawsuit filed against Vistagen Therapeutics for alleged false statements regarding drug trial data. Investors who purchased securities April 2024-December 2025 may be eligible.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Investors Face March Deadline in Securities Litigation Over Trial Disclosures

Vistagen investors face March 16, 2026 deadline in securities lawsuit alleging false statements about drug trials and clinical data that misled shareholders.
VTGNsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Securities Litigation: Investors Face March Deadline to Join Class Action

Vistagen faces securities class action over alleged misleading statements about drug fasedienol. Investors who purchased stock April 2024-December 2025 can join by March 16, 2026 deadline.
VTGNinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Schall Law Firm Opens Class Action Against Vistagen Over PALISADE-2 Trial Disclosures

Schall Law Firm launches securities fraud class action against Vistagen for allegedly making misleading statements about fasedienol drug trial prospects, affecting investors from April 2024 to December 2025.
VTGNsecurities fraudclass action lawsuit